Schrödinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, announced on January 4, 2019, the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its drug discovery pipeline. The Bill and Melinda Gates Foundation Trust and WuXi AppTec’s Corporate Venture Fund co-led the round, joined by leading life science and technology investors Deerfield Management, Baron, Qiming Venture Partners and GV (formerly Google Ventures).
The WilmerHale team representing Schrödinger in the round was led by Cynthia Mazareas and included Scott Lunin and Andrea Sorrentino.